Subscribe
shutterstock-167404766-web
JrCasas / Shutterstock.com
2 December 2014Asia-Pacific

Otsuka acquires Avanir in $3.5 billion deal

Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Drug makers on brink of $65bn patent cliff, says report
12 December 2014   Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024

More on this story

Big Pharma
Drug makers on brink of $65bn patent cliff, says report
12 December 2014   Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.

More on this story

Big Pharma
Drug makers on brink of $65bn patent cliff, says report
12 December 2014   Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.

More features

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course
Drug approvals up but global innovation declines
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
Court denies Regeneron bid to halt copy of blockbuster eye drug
Interview: Klaus Grabinski, UPC Court of Appeal president
Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird